Research news Archives - Page 23 of 33 - Institute for Bioengineering of Catalonia

December 5, 2016November 22, 2016

Record-breaking nanojets that use safe fuel

IBEC group leader and ICREA research professor Samuel Sanchez’s latest nanojets have set a new world record for the smallest man-made jet engine ever.

As well as using a safe new method of propulsion, the tubular nanoscale engines are also three times smaller than the previous Guinness Book of Records entry – which was also set by Samuel, in a collaboration with colleagues at the Leibniz Institute for Solid State and Materials Research in Dresden.

October 27, 2016October 27, 2016

Molecules activated by light to control glutamate receptors

Researchers at IBEC, IQAC-CSIC and CNRS have developed molecules that can modulate the activity of glutamate receptors in the central nervous system, with important applications in biomedicine.

For the last few years the collaborators have been working on the development of molecules called targeted covalent photoswitches (TCPs), whose structure can be changed using light. This change in shape causes the molecule to be recognized – or not – by a biological receptor as a key is to a lock. This coupling activates the receptor or not, triggering the activity.

October 25, 2016October 13, 2016

Drug-loaded nanovectors covered with antibodies represent an innovative approach to combat malaria

A study led by Xavier Fernández Busquets, director of the joint ISGlobal-IBEC Nanomalaria unit, describes an innovative approach to selectively eliminate red blood cells infected by Plasmodium falciparum, avoid their aggregation, and inhibit parasite growth.

The strategy, based on the use of nanovesicles coated with antibodies that target a parasite protein, and loaded with an antimalarial drug, represents a promising alternative in the treatment of severe malaria.

October 13, 2016September 9, 2016

Cells move en masse towards rigid tissues

A new phenomenon, collective durotaxis, opens new avenues to control tumor growth and improve wound healing

In a study published today in the journal Science, researchers at IBEC have shown that several types of cells are attracted to the most rigid areas of tissues. The discovery contradicts the traditional view that cell movement is guided primarily by variations in the chemical concentration of proteins and ions.

July 21, 2016July 20, 2016

Vision restoration by molecular prostheses

A new route towards treatment to recover sight based on controlling the activity of small molecules

The groups of Pau Gorostiza, ICREA Research Professor at IBEC, and Amadeu Llebaria of IQAC-CSIC have developed molecules that can be applied as light-regulated molecular prostheses to help restore vision in cases of retinal degeneration.

Together with their collaborators at ICIQ, INA, IRB Barcelona, CIBER-BBN and the Miguel Hernández and Alcalá de Henares universities, the researchers reveal in Nature Communications today their development of a new class of light-regulated drug, targeted covalent photoswitches (TCPs), that act as prosthetic molecules that can restore photoresponses in degenerated retinas.

June 23, 2016

Mycobacterium in olive oil for cancer treatment

Researchers at the Autonomous University of Barcelona (UAB) and Institute for Bioengineering of Catalonia (IBEC) have revealed a way to effectively deliver a mycobacterium needed for the treatment of bladder cancer in humans –using a formulation based on olive oil.

The researchers have found a way to reduce the natural clumping that occurs when mycobacteria cells, which possess a high content of lipids in their walls, are introduced to the usual aqueous solutions that are used for intravesical instillation in bladder cancer patients. This clumping may interfere with the interaction of the mycobacteria-host cells and negatively influence their antitumor effects.

June 10, 2016

Using 3D printing to produce crucial research tools

With 3D printing set to revolutionise research, IBEC researchers have been exploring the possibilities of using the new technology to already improve their processes and methods.

IBEC recently became home to the first 3D bioprinter in Catalonia, which promises to open up exciting new avenues in tissue and organ regeneration. First, though, in a collaboration with the UPF, the CINVESTAV-Monterrey in Mexico, and the University of Washington, the Barcelona-based scientists developed a new way of producing microfluidic devices – systems in which low volumes of fluids are processed.

June 10, 2016June 3, 2016

Reaching new depths: a non-invasive solution for the activation of proteins in deep tissues

Researchers at IBEC and their collaborators at the Centre of Regenerative Medicine of Barcelona (CMR[B]) have developed a revolutionary new technique based on photoactivation (light activation), by which cells in deep tissue can activated and tracked in vivo without causing any damage.

Manipulating protein expression to monitor cell behavior is a powerful tool in the field of biology.

May 30, 2016May 19, 2016

Researchers generate human heart grafts from human pluripotent stem cells

Scientists from IBEC, in collaboration with the Hospital General Universitario Gregorio Marañón in Spain and two other groups in the USA, have made a big leap in heart regeneration advances by achieving heart grafts from human pluripotent stem cells for the first time in less than one month.

The collaborators, working in Spain and the USA, describe in the journal Biomaterials how they decellularized human hearts, all of which had been determined not suitable for transplantation by the Spanish National Transplant Organization. They left the extracellular matrix, the structure that provides cells with structural and biochemical support, intact.

May 23, 2016May 17, 2016

Looking to the ocean for malaria solutions

Researchers have found heparin-like molecules with reduced blood-thinning activity that can be used for therapeutic approaches against malaria – in sea cucumbers, red algae and marine sponges.

Until now, heparin – which has been shown to have antimalarial activity and specific binding affinity for red blood cells infected with the Plasmodium malaria parasite – has not been explored for anti-malarial drug solutions due to its powerful anticoagulating activity. While heparin is able to block the cell adhesion of infected red blood cells to various host receptors and disrupt the growth of the pathogen, its downfall is that the quantities needed for malaria treatment would result in too much blood-thinning and bleeding. There’s also the potential risk of infection, since polysaccharides such as heparin tend to be obtained from mammals.